Because of the unpredictable hypotensive effect and serious complications during continuous-wave cyclophotocoagulation (CW-CPC), the use of this method in the treatment of glaucoma is limited. Therefore, a new technique was developed, known as micropulse trans-scleral cyclophotocoagulation (MP-CPC). During MP-CPC, a series of short bursts of laser pulses deliver energy to the ciliary body at the near-infrared wavelength of 810 nm, which is strongly absorbed by melanin. As shown by experimental studies, there are several acting mechanisms which reduce IOP decrease during MP-CPC. In clinical studies, patients with different forms and stages of glaucoma received laser energy of similar parameters during MP-CPC. It may be concluded that MP-CPC is a safe and effective alternative to traditional CW-CPC. However if laser irradiation directed to the ciliary body during MP-CPC gets longer, the incidence of complications increases. The variation of glaucoma forms in patients who underwent MP-CPC and a relatively small number of cases involved in the studies prevent us from making an unambiguous recommendation of this technique at the moment. An extensive research of the technique is required.
25 June 2019 in Modern technologies in ophtalmology
Despite the well-known effectiveness of pharmacological glaucoma therapy, surgical approach remains one of the main treatment options for some forms and stages of the disease. The long-term success of glaucoma surgery depends on the intensity of local wound healing processes at the surgical site. The most common way to influence healing processes in surgical treatment of glaucoma is the use of antimetabolites. However, given the high risk of serious complications associated with their use, the search for new drugs devoid of these disadvantages continues. The aim of this review is to describe the efficacy and safety of both currently used and upcoming pharmacological ways to influence the wound healing process after glaucoma surgery in order to improve the stability of hypotensive effect.
Postkeratoplasty glaucoma develops after cornea transplantation in 10–53 % cases. For ophthalmotonus stabilization in patients, it was proposed to use micropulse laser surgery.Purpose. To evaluate the effectiveness of micropulse laser surgery in patients with secondary refractory glaucoma after keratoplasty.Patients and methods. The study included 27 eyes after different types of keratoplasty. The average level of intraocular pressure was 33.2 ± 3.7 mmHg, the average number of hypotensive drops was 2.9 ± 0.7. Visual acuity varied from incorrect light perception to 0.3 with correction. Micropulse laser treatment was performed with the standard settings and a power of 2800 mW.Results. On the first day after laser surgery, 24 patients had a decrease in IOP by an average of 24 % to 25.6 ± 3.3 mmHg. Three patients had a reactive increase in IOP by an average of 5 % to 33–36 mmHg. After 12 months of follow-up, the average IOP level was 24.9 ± 1.8 on the hypotensive drops, a decrease of IOP was 24.5 %, the number of hypotensive drops was reduced to 2.1 ± 0.7. In 6 cases, an increase in visual acuity by 1–2 lines was diagnosed due to a decrease in corneal edema. In 3 cases, 1–2 months after laser surgery, patients underwent second transplantation of the Descemet membrane. However, in 2 patients, an IOP increased again to 27–30 mmHg, and it was decided to conduct a repeated micropulse surgery with a power of 2800 mW. When observed for up to 3 months, IOP respond to the target level and averaged 18-20 mmHg. Using ultrasound biomicroscopy, the dynamics of changes in the thickness of the ciliary body was followed in all patients, the average thickness before surgery was 0.56 ± 0.11 mm. After 12 months, there was no statistical difference with the preoperative thickness, the average values were 0.55 ± 0.10 mm, the safety of its main structures was noted.Conclusion. Micropulse cyclophotocoagulation is an effective and safe method of treating secondary refractory glaucoma in the eyes both before keratoplasty and after repeated cornea transplantation, which opens up new prospects in the treatment of glaucoma combined with corneal diseases.
Background: Neovascular glaucoma (NVG) is a highly refractory form, it is characterized by fast development and a high level of the intraocular pressure (IOP). Aims: To evaluate the effectiveness of micropulse transscleral cyclophotocoagulation (mCPC) in the combined treatment of patients with secondary neovascular glaucoma. Methods: The study included 32 patients (32 eyes) with secondary NVG as an outcome of diabetes mellitus and (or) thrombosis of the central retinal vein or its branches. The preoperative IOP averaged 38.88.8 mm Hg with the most intense hypotensive therapy. All the patients underwent mCPC. In the postoperative period, the patients were examined on the first day after the operation, then in 1 week, 1, 3, 6 months, 1 year after the operation. Results: All the operations were performed without complications. Pain syndrome in all cases was stopped on the first day after surgery. Six patients had reactive hypertension on the first day, therefore, the hypotensive therapy was intensified. The IOP 1 week after mCPC was 20.97.9 mm Hg, after 1 month of observation 23.76.0 mm Hg with the hypotensive therapy. 34 weeks post-surgery, six patients with the preserved visual function experienced a repeated IOP increase, and the Ahmed valve was implanted. 6 months after mCPC, the IOP level averaged 22.87.7 mm Hg with the hypotensive therapy. Against the background of the IOP compensation, anti-VEGF drugs were injected in 4 cases, followed by laser coagulation of the retina. Conclusion: Application of mCPC in NVG glaucoma patients showed only a small number of postoperative complications. This method of laser treatment can be used in combination with panretinal laser coagulation before or after the surgery, including administration of anti-VEGF drugs before or after the surgery. In case of the IOP increase, mCPC may be repeated.